Jenny Murase, MD
Dermatology · Mountain View, CANPI 1346371382
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $837,576 of the $1,050,670 with a category attached, or 79.7%. It is spread thinly across 24 manufacturers, the largest accounting for just 23.8%. 2025 is the largest year on record at $549,899, 9.4 times the $58,563 reported in 2019. Among dermatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,052 payments — averaging $998.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$250K
- Regeneron Healthcare Solutions, Inc.$248K
- Sanofi$229K
- Galderma Laboratories, L.p.$158K
- Lilly USA, LLC$82K
- LEO Pharma Inc.$29K
- plus $54K from 18 others
What the payments were for
- Consulting fees$131,55913%
- Speaking & faculty fees$837,57680%
- Travel & lodging$62,2046%
- Food & beverage$18,8762%
- Education$4540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 287 | $250,164 |
| Regeneron Healthcare Solutions, Inc. | 223 | $248,291 |
| Sanofi | 132 | $228,834 |
| Galderma Laboratories, L.p. | 150 | $157,749 |
| Lilly USA, LLC | 93 | $81,982 |
| LEO Pharma Inc. | 42 | $29,227 |
| AbbVie | 29 | $22,131 |
| E.r. Squibb & Sons, L.L.C. | 13 | $7,371 |
| UCB SA | 22 | $6,999 |
| Pfizer | 15 | $6,312 |
| Eli Lilly | 8 | $4,181 |
| Sanofi US Services Inc. | 1 | $2,870 |
| Arcutis Biotherapeutics, Inc. | 6 | $2,755 |
| Allerderm Laboratories | 1 | $1,000 |
| Novartis | 9 | $196 |
| Regeneron | 4 | $140 |
| Johnson & Johnson | 4 | $107 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Incyte Corporation | 4 | $87 |
| Amgen | 2 | $60 |
| Genentech USA, Inc. | 2 | $44 |
| Organon | 2 | $28 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $23 |
| Verrica Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,050,670 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 178 | $698,815 |
| Dupixent PenDupilumab | 66 | $256,438 |
| RinvoqUpadacitinib | 22 | $136,108 |
| SotyktuDeucravacitinib | 18 | $118,584 |
| XolairOmalizumab | 16 | $48,064 |
| Tacrolimus | 55 | $5,164 |
| Clobetasol Propionate | 111 | $4,656 |
| Tretinoin | 32 | $2,585 |
| Fluocinonide | 63 | $2,170 |
| Hydroxyzine Hcl | 84 | $2,037 |
| Triamcinolone Acetonide | 89 | $1,819 |
| Fluorouracil | 22 | $1,658 |
| Desonide | 34 | $1,453 |
| Azelaic Acid | 14 | $1,282 |
| Hydroxychloroquine Sulfate | 13 | $1,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $22,131 | $136,10822 claims |
| E.r. Squibb & Sons, L.L.C.Sotyktu | $7,371 | $118,58418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,875 dermatology providers in California.
Other dermatology in Mountain View
- Amit PandyaMountain View$321K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.